American CryoStem Welcomes Noted Cryopreservation Expert, Dr. Dayong Gao, to Medical & Scientific Advisory Board
24 Junio 2013 - 7:30AM
American CryoStem Corporation (OTCQB:CRYO), a
leading strategic developer, marketer and global licensor of
patented adipose tissue-based cellular technologies for the
Regenerative and Personalized Medicine industries, today announced
that Dayong Gao, Ph.D. has been appointed to the Company's Medical
and Scientific Advisory Board.
Dr. Gao is a world-renowned Professor of Mechanical Engineering
and Biomedical Engineering at the University of Washington in
Seattle. He has been actively engaged in cryopreservation research
for more than 20 years, with specific emphasis on fundamental and
applied cryobiology, which is the investigation of mechanisms in
cryoinjury and cryoprotection with respect to living biological
systems at low temperatures; with the development of optimal
methods and technologies for the cryopreservation; and with the
banking of living cells and tissues for biomedical
applications.
Dr. Gao has published 175 research papers in prestigious
scientific/biomedical journals, with over 250 papers/abstracts in
conference proceedings. He has obtained 16 patents, and
authored two scientific books and numerous chapters in 17
scientific books. He currently serves on the Editorial Board,
as Editor-in-Chief, of six scientific journals, and is the Editor
of the Cryopreservation Engineering section of Biopreservation and
Biobanking. His research in cryobiology and cryopreservation has
been funded by the National Institutes of Health, the American
Cancer Society, the Bill and Melinda Gates Foundation, the American
Heart Association, the Whitaker Foundation, the Washington Research
Foundation and the Kentucky Science Foundation, among others. Dr.
Gao graduated with B.Sc. degree from the University of Science and
Technology in China, and received a Ph.D. in Mechanical Engineering
from Concordia University, Montreal, Canada.
Commenting on his appointment, Dr. Gao said, "My initial meeting
in New Jersey with management and the laboratory team, along with
the review of their scientific procedures, revealed the highest
quality collection, processing and storage methodologies
commercially available today. The Company's proprietary adult stem
cell differentiation mediums and cell expansion methodology is
cutting edge. I look forward to working with American CryoStem and
its distinguished Medical and Scientific Advisory Board members to
enhance the technical and commercial advancement of the Company's
adipose tissue processing and storage technologies and
platforms."
"Dr. Gao's unparalleled clinical research and expertise in the
field of cryopreservation and its impact on implementing
bio-banking protocol will provide invaluable guidance and
enhancement of our Company's ongoing development and
commercialization efforts," stated John S. Arnone, Chairman and CEO
of American CryoStem Corporation.
About American CryoStem Corporation
A pioneer in the fields of Regenerative and Personalized
Medicine, American CryoStem is a developer, marketer and global
licensor of patented adipose tissue-based cellular technologies and
related proprietary services with a focus on clinical processing,
commercial bio-banking and application development for adipose
(fat) tissue and autologous adipose-derived regenerative cells
(ADRCs). The Company maintains a strategic portfolio of
intellectual property and patent applications that form its Adipose
Tissue Processing Platform, which supports and promotes a growing
pipeline of biologic products and processes, clinical services and
international licensing opportunities. Through its ACS
Laboratories division, the Company operates an FDA registered, cGMP
compliant human tissue processing, cryo-storage, cell culture and
differentiation media development facility in Mount Laurel, New
Jersey.
For more information, please visit
www.americancryostem.com and
www.acslaboratories.com.
Forward Looking Statements
This press release may contain forward-looking statements,
including information about management's view of American CryoStem
Corporation's ("the Company") future expectations, plans and
prospects. In particular, when used in the preceding
discussion, the words "believes," "expects," "intends," "plans,"
"anticipates," or "may," and similar conditional expressions are
intended to identify forward-looking statements. Any
statements made in this press release other than those of
historical fact, about an action, event or development, are
forward-looking statements. These statements involve known and
unknown risks, uncertainties and other factors, which may cause the
results of the Company, its subsidiaries and concepts to be
materially different than those expressed or implied in such
statements. Unknown or unpredictable factors also could have
material adverse effects on the Company's future results. The
forward-looking statements included in this press release are made
only as of the date hereof. The Company cannot guarantee
future results, levels of activity, performance or
achievements. Accordingly, you should not place undue reliance
on these forward-looking statements. Finally, the Company
undertakes no obligation to update these statements after the date
of this release, except as required by law, and also takes no
obligation to update or correct information prepared by third
parties that are not paid for by American CryoStem Corporation.
CONTACT: Hanover|Elite
Kathy Addison, Chief Operating Officer
407-585-1080 or via email at CRYO@hanoverelite.com
American Cryostem (CE) (USOTC:CRYO)
Gráfica de Acción Histórica
De May 2024 a Jun 2024
American Cryostem (CE) (USOTC:CRYO)
Gráfica de Acción Histórica
De Jun 2023 a Jun 2024